These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 16954432)

  • 21. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Jul; 13(14):1-2, 5. PubMed ID: 12518771
    [No Abstract]   [Full Text] [Related]  

  • 24. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-reducing strategies for breast cancer--a review of recent literature.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
    Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK
    Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer.
    Aguas F; Martins A; Gomes TP; de Sousa M; Silva DP;
    Maturitas; 2005 Nov; 52 Suppl 1():S23-31. PubMed ID: 16126355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.
    Iwase H
    Breast Cancer; 2008; 15(4):278-90. PubMed ID: 18810576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant endocrine therapy for early breast cancer.
    Andreetta C; Smith I
    Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
    Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
    Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
    Saji S; Kuroi K
    Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
    Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aromatase inhibitors in the management of early breast cancer.
    Nabholtz JM
    Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SERMs: meeting the promise of multifunctional medicines.
    Jordan VC
    J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endogenous hormone metabolism as an exposure marker in breast cancer chemoprevention studies.
    Kaaks R
    IARC Sci Publ; 2001; 154():149-62. PubMed ID: 11220654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
    Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.